Myriad Genetics

At World CB & CDx Europe: Featured Plenary Session 🎤 Myriad will host a sponsored 30-minute plenary session highlighting how ultra-sensitive MRD testing is being applied across real-world clinical and developmental settings. 🧪 Clinical Validation of Myriad Genetics' Ultra-Sensitive Pan-Cancer WGS-Based Precise MRD Assay Speaker: Dale Muzzey, PhD, Chief Scientific Officer, Myriad Genetics This deep-dive session will explore where tumor-informed, ultra-sensitive MRD testing delivers value today, and how biopharma teams can apply these approaches across their own development programs. 📅 Wednesday, April 1, 2026 | 8:50 AM BST #PrecisionMedicine #CDx #CompanionDiagnostics #ClinicalDevelopment #Biopharma #Oncology #GlobalTrials #MRD #MyriadGenetics #SOPHiAGENETICS

Today, we celebrate Medical Science Liaison Day and recognize the outstanding MLSs serving as knowledgeable scientific partners and expert resources across Myriad. 🔬 Medical Science Liaisons play a critical role in driving our mission of advancing health and well-being for all forward. To our MSL colleagues across Myriad: Thank you for your expertise, unwavering commitment, and all that you do to impact the clinicians and patients we serve. 👏 #InternationalMSLDay #teamMyriad

Accelerating CDx Development for Global Precision Medicine 🌍🧬 We're looking forward to connecting in London at the 16th World CB & CDx Summit Europe, where Myriad Genetics and SOPHiA GENETICS will co-host a dedicated Engager exploring how biopharma can accelerate companion diagnostic (CDx) development and global deployment, without adding operational burden. 👉 What You'll Learn: 🔵How a modern CDx partnership model can accelerate clinical studies and reduce execution risk 🔵What CTA-to-CDx co-development looks like in practice: from early validation through trial enrollment 🔵How centralized testing and distributed deployment can support global scale and patient access 🔵Why the Myriad-SOPHiA GENETICS collaboration represents a strategic advantage for late-stage development and commercialization 👉Featured Speakers: Jess Lambe | Louis Welebob | Tina McGuire | Julien Pontis | Vern Geckler | Yves Serroen | Drew Gibbs | Janni Mirosevich, Ph.D. | Dale Muzzey | Michael Senior | Jonathan Beer | Brian Baker 📅 March 30, 2026 | 2:30 - 4:30 PM BST 📍 Novotel London West 👉 This is an invitation-only session. If you are interested in attending this pre-conference Engager or the World CB & CDx London, please fill out this form: https://brnw.ch/21x14cb #PrecisionMedicine #CDx #CompanionDiagnostics #ClinicalDevelopment #Biopharma #Oncology #GlobalTrials #MRD #MyriadGenetics #SOPHiAGENETICS

Proud to share that Myriad Genetics' abstract on enhancing breast cancer risk assessment in a community imaging center has been selected as an Abstract Award Winner at NCBC National Consortium of Breast Centers 2026, and will be featured on-site as one of only three oral presentations at this week's conference. This recognition highlights the importance of advancing risk assessment in real-world care settings and expanding access to patients so they can make more informed decisions regarding their care. The presentation at NCBC will be given this Saturday, March 28 during the poster reception. We look forward to sharing these insights with all in attendance. #breastcancer #research #ncbc

Powered by AMPLIFY® technology, the Prequel® Prenatal Screen delivers high sensitivity and specificity for common chromosomal conditions, even in challenging samples. As early as week eight, Prequel uses cell-free DNA (cfDNA) to determine if a pregnancy is at an increased risk for a chromosome change leading to conditions such as Down, Edwards, or Patau syndromes. These results give your patients more time and information to plan and prepare. Learn more about how Prequel supports your practice: https://lnkd.in/g_--4jiW. #prenatal #geneticinsights #healthcareprofessionals

In the latest episode of the SHE MD Podcast, Dr. Thais Aliabadi and Mary Alice Haney sit down with Dr. Beth Moore to discuss #coloncancer, its rise in women under 50, and what women should know about risk factors, colonoscopies, and the important role of screening. Education can be a critical bridge toward earlier detection, informed decision-making, and better outcomes. At Myriad, we're proud to support and amplify conversations like these while advancing health and well-being for all. 🎧 Listen to the full episode: https://lnkd.in/ggSe4dGt #genetictesting #cancerrisk

Proud to have partnered with BioHive Utah and Women Tech Council to support an inspiring #InternationalWomensDay event earlier this month, where we brought together a community dedicated to empowering each other. Speakers like Salt Lake City mayor Erin Mendenhall and other notable leaders shared powerful stories, actionable advice, and personal guidance on how to make an impact. Thank you to everyone who attended and contributed to this meaningful event. Together, we continue to build strong communities and create opportunities for women to thrive. 💙 #iwd #saltlakecity #teamMyriad

When patients like Malory face inconclusive results, uncertainty can delay critical decisions. Luckily, providers like Dr. Christian Briery know that the Prequel® Prenatal Screen offers early, reliable insights that can help you guide care with confidence. With AMPLIFY® technology, Prequel delivers exceptional sensitivity and specificity even in low fetal fraction cases as early as eight weeks, helping you detect what other screens might miss. Prequel is not designed or clinically validated to screen for or assess maternal health conditions, including maternal malignancies. And while incidental maternal findings are rare, its comprehensive analysis can support clinical follow-up and timely decision-making when results are unexpected. Hear Malory's story and learn how Prequel can support your patients and your practice here: https://lnkd.in/g_--4jiW. #prental #geneticinsights #myriadgenetics

Today we announced that the U.S. Food and Drug Administration (FDA) has approved the MyChoice® CDx Test as the Companion Diagnostic (CDx) for Zejula® (niraparib), a PARP inhibitor from GSK, for patients with advanced ovarian cancer. Read more: https://lnkd.in/ggfY9p4X

Proud to see our work with S50 recognized at the Cancer Awareness Advertising Awards. This campaign was designed to do more than raise awareness during Hereditary Cancer Awareness Month and Breast Cancer Awareness Month; it aimed to help women better understand hereditary #cancerrisk and the important role of comprehensive #genetictesting. Thank you to our teams and partners who helped bring this to life and inspire action around prevention and early detection. 💙